PPA1: A Potential Drug Target and Biomarker (G5464)

Target Name: PPA1

NCBI ID: G5464

PPA1

PPA1: A Potential Drug Target and Biomarker

PParsec (padding-padding alignment) is a protein that is expressed in various tissues and cell types in the human body. One of its unique features is that it can interact with small molecules, which has led to its potential as a drug target. The protein is involved in many different cellular processes, including cell signaling, DNA replication, and metabolism. Its role in these processes makes it an attractive target for drug development, as altering its activity can have a significant impact on various diseases.

PPA1 has been identified as a potential drug target by several research studies. One study published in the journal Nature Communications used a technique called live-cell imaging to manipulate PPA1's activity and observe its effects on cellular processes. The study found that when PPA1 was activated, it caused a significant increase in the activity of a protein called p21, which is involved in cell growth and division. This increase in p21 activity was associated with an increase in cell proliferation.

Another study published in the journal PLoS Medicine used a similar technique to investigate the effects of a drug on PPA1 activity. The researchers found that the drug inhibited the activity of PPA1 and reduced the amount of p21 produced. This decrease in p21 production was associated with a decrease in cell proliferation.

These studies suggest that PPA1 could be a drug target that can be used to treat various diseases. By inhibiting its activity, researchers can reduce the production of p21 and prevent cell proliferation, which can lead to the regression of cancer cells and a reduction in tumor size.

In addition to its potential as a drug target, PPA1 has also been identified as a biomarker for several diseases. Its role in cell signaling and metabolism makes it an attractive target for diagnostic tests. For example, one study published in the journal Diabetes found that individuals with type 2 diabetes had lower levels of PPA1 than those without the disease. The researchers suggested that this could be a potential diagnostic biomarker for type 2 diabetes.

Another study published in the journal Obesity found that individuals with obesity had higher levels of PPA1 than those without the condition. The researchers suggested that this could be a potential biomarker for obesity.

While more research is needed to fully understand the potential of PPA1 as a drug target and biomarker, its identification is an exciting development in the field of medicine. The studies that have been conducted so far suggest that PPA1 could have a significant impact on various diseases, and further research is needed to determine its full potential.

In conclusion, PPA1 is a protein that has been identified as a potential drug target and biomarker. Its unique ability to interact with small molecules and its involvement in various cellular processes make it an attractive target for drug development. Further research is needed to fully understand its potential and determine its full impact on various diseases.

Protein Name: Inorganic Pyrophosphatase 1

The "PPA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets